Patents by Inventor Catherine Massacrier

Catherine Massacrier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TLR3 BINDING AGENTS
    Publication number: 20160347853
    Abstract: The present invention relates to antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind TLR3, and that optionally further modulate, e.g. inhibit, signaling. The invention also relates to cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to diagnose, treat or prevent diseases, e.g. autoimmune diseases, inflammatory diseases and the like.
    Type: Application
    Filed: July 7, 2016
    Publication date: December 1, 2016
    Inventors: Laurent Gauthier, Catherine Massacrier, Yannis Morel, Carine Paturel
  • TLR3 binding agents
    Patent number: 9388246
    Abstract: The present invention relates to antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind TLR3, and that optionally further modulate, e.g. inhibit, signaling. The invention also relates to cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to diagnose, treat or prevent diseases, e.g. autoimmune diseases, inflammatory diseases and the like.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: July 12, 2016
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Catherine Massacrier, Yannis Morel, Carine Paturel
  • TLR3 BINDING AGENTS
    Publication number: 20140065154
    Abstract: The invention provides anti-TLR3 antibodies as well as methods of making and using them. The antibodies are particularly adapted to the treatment of autoimmune or inflammatory diseases using anti-TLR3 antibodies.
    Type: Application
    Filed: January 10, 2012
    Publication date: March 6, 2014
    Applicant: INNATE PHARMA
    Inventors: Laurent Gauthier, Catherine Massacrier, Yannis Morel, Carine Paturel, Cecile Bonnafous, Mette Dahl Andersen, Benjamin Rossi
  • TLR3 BINDING AGENTS
    Publication number: 20120034232
    Abstract: The present invention relates to antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind TLR3, and that optionally further modulate, e.g. inhibit, signaling. The invention also relates to cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to diagnose, treat or prevent diseases, e.g. autoimmune diseases, inflammatory diseases and the like.
    Type: Application
    Filed: May 5, 2011
    Publication date: February 9, 2012
    Applicant: Innate Pharma
    Inventors: Laurent Gauthier, Catherine Massacrier, Yannis Morel, Carine Paturel